Are CV studies worth it for diabetes meds? After Merck and Sanofi's recent successes, some say no

Earlier this week, diabetes drugmakers Merck ($MRK) and Sanofi ($SNY) rolled out data showing their meds--Januvia and Lyxumia, respectively--passed heart safety tests, turning up no red flags in postmarketing studies. And now, some industry watchers are wondering whether those large, expensive trials--which aren't long enough to establish long-term outcomes--were worth it. Story | More on Januvia | More on Lyxumia

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.